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1. Introduction
The interaction of a drug with a serum protein is important 
in determining the activity and fate of such a compound with-
in the body. For instance, these interactions help determine the 
overall distribution, excretion, and toxicity of a drug [1–4]. 
One protein known to interact with many drugs is human se-
rum albumin (HSA). HSA is the most abundant protein in se-
rum, having a typical concentration of 50 g/l [3, 4]. HSA has 
a molar mass of 66,438 g/mol and consists of a single chain 
of 585 amino acids held together by 17 disulfi de bonds [3, 
4]. Many small organic compounds show reversible binding 
to HSA, including long-chain fatty acids, steroids, warfarin, 
tryptophan, ketoprofen, propranolol, and diazepam [5–8].
There are numerous techniques for examining solute bind-
ing to HSA. Examples include ultrafi ltration, equilibrium di-
alysis, UV–vis spectroscopy, spectrofl uorometry, crystallog-
raphy, capillary isotachophoresis and affi nity capillary elec-
trophoresis, among others (see References [3, 5–17] and ref-
erences cited therein). Another technique that has been used 
for such work is high-performance affi nity chromatography 
(HPAC) [18–27]. This is typically performed by examining 
the retention and competition of solutes as they pass through 
an immobilized HSA column. Examples include reports in 
which HSA columns have been used to measure the binding 
strength of solutes with HSA, perform competition and dis-
placement studies, generate structure-retention relationships, 
and locate binding regions on this protein [18, 23–26]. Advan-
tages of this approach include its speed, precision, and good 
correlation versus reference methods [18].
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It is important in such experiments to have a support that 
provides good activity for the immobilized HSA and low non-
specifi c binding for the drug of interest. The Schiff base meth-
od has often been used to immobilize HSA for this purpose 
and meets these requirements for many drugs [19–23]. How-
ever, this is not the case for all drugs that have been tested. 
For instance, in one recent study it has been observed that car-
bamazepine has signifi cant secondary interactions with silica 
supports prepared by the Schiff base method [27]. Thus, it is 
desirable in this case to fi nd an alternative technique for im-
mobilizing HSA within an HPLC column.
This study will examine the use of HSA columns that have 
been prepared using N-hydroxysuccinimide (NHS)-activated 
silica. Frontal analysis and zonal elution will be used to com-
pare the behavior of these columns with those made by the 
Schiff base method. Carbamazepine will be used as the mod-
el drug for this report. This work will compare the equilibri-
um constants, binding capacities, and specifi c activities for the 
HSA columns, as well as their non-specifi c interactions with 
carbamazepine. The non-specifi c interactions of these col-
umns with a variety of other drugs will also be considered and 
will be compared to those obtained with an alternative im-
mobilization method for HSA (e.g., the carbonyldiimidazole 
or CDI method) [18]. From the results it will be possible to 
determine the advantages of each immobilization technique 
when it is used to prepare HSA columns for experiments with 
carbamazepine. In addition, these data should provide some 
useful insights into the testing and development of HSA col-
umns for other compounds.
2. Experimental
2.1. Reagents
The carbamazepine (>98% pure), sodium nitrate, disuccinimi-
dyl carbonate (DSC), digitoxin (>99% pure), lidocaine (>98% 
pure), propranolol hydrochloride (>99% pure), pindolol (97% 
pure), ibuprofen (>98% pure), tryptophan (>98% pure), vera-
pamil hydrochloride (>99% pure), phenytoin (>99% pure), 
warfarin (>98% pure) and 1,1′-carbonyldimidazole were ob-
tained from Sigma (St. Louis, MO, USA). Human serum albu-
min (Cohn fraction V, essentially fatty acid and globulin free) 
was purchased from Fluka (Milwaukee, WI, USA). The pyr-
idine, triethylamine and 3-glycidoxypropyltrimethoxysilane 
(98% pure), and dimethylsulfoxide (DMSO, >99% pure) were 
from Aldrich (Milwaukee, WI, USA). Nucleosil Si-300 (7 μm 
particle diameter, 300 Å pore size) was purchased from Mach-
erey Nagel (Düren, Germany). Reagents for the bicinchonin-
ic acid (BCA) protein assay were from Pierce (Rockford, IL, 
USA). Other chemicals used in this report were of the highest 
grades available. All buffers and aqueous solutions were pre-
pared using water from a Barnstead Nanopure water system 
(Dubuque, IA, USA) and fi ltered through Osmonics 0.22 μm 
nylon fi lters from Fisher (Pittsburgh, PA, USA).
2.2. Apparatus
The chromatographic system consisted of a PU-980i isocrat-
ic pump and P4000 gradient pump from Jasco (Tokyo, Japan), 
and one UV100 absorbance detector from ThermoSeparation 
Products (Riviera Beach, FL, USA). Samples were applied 
using a Rheodyne LabPro valve (Cotati, CA, USA) equipped 
with a 20 μl sample loop. The BCA protein assay and NHS as-
say were performed on a Shimadzu UV-160A spectrophotom-
eter (Kyoto, Japan). An Isotemp 9100 circulating water bath 
from Fisher was used for temperature control of both the col-
umns and mobile phases. All columns were downward slurry 
packed at 3500 psi (24 MPa) using an Alltech HPLC column 
slurry packer (Deerfi eld, IL, USA). Chromatographic data 
were collected and processed using programs written in Lab 
View 5.1 (National Instruments, Austin, TX, USA).
2.3. Preparation of NHS-activated silica
Nucleosil Si-300 was converted into an NHS-activat-
ed form by reacting this support with DSC in the presence 
of pyridine and triethylamine, as shown in Figure 1 [28]. Pri-
or to this reaction, the silica was pretreated by combining 3 g 
Figure 1.  Preparation of NHS-activated silica for protein immobilization. 
140                                       KIM, MALLIK, & HAGE IN JOURNAL OF CHROMATOGRAPHY B 837 (2006)
of this material with 16% (v/v) hydrochloric acid and refl ux-
ing at 110 °C overnight. This support was then washed several 
times with water and fi ltered using a 0.22 μm nylon fi lter. The 
recovered silica was dried overnight under vacuum at 150 °C. 
The dried silica was next transferred to a 150 ml round 
bottom fl ask and combined with 50 mg DSC. Dry acetone 
(20 ml) was added to this fl ask while the silica suspension was 
gently agitated with a stirring bar. Triethylamine (2.5 ml) was 
mixed with dry pyridine (20 ml) and placed drop wise into the 
silica suspension under an argon atmosphere over the course 
of 30 min. This mixture was gently agitated for an addition-
al 60 min, followed by six washes with acetone to remove 
any remaining DSC. The fi nal support was dried under vac-
uum overnight at room temperature and stored in a dessica-
tor at room temperature. In addition, a portion of this material 
was packed into a 2.1 mm i.d. × 3.5 cm or 5.0 cm column for 
use in non-specifi c binding studies.
Activated sites on the surface of this support were quan-
titated by measuring the NHS groups released into so-
lution after hydrolysis [29]. This gave a value of 13.8 
(±0.3) μmol activated groups/g silica (±1S.D.) for the support 
used in this study. With this same assay, it was determined 
that the NHS-activated silica was stable for over 6 months un-
der the given storage conditions, with only a 10% decrease in 
active groups being noted over this period.
2.4. Preparation of Schiff base-activated support
In the Schiff base method, Nucleosil Si-300 silica was fi rst 
converted into a diol-bonded form according to a previous pro-
cedure [30]. This was performed by placing 5 g Nucleosil Si-
300 in 25 ml of pH 5.5, 0.1 M sodium acetate buffer (Note: 
The pH of this buffer was adjusted by adding a small amount 
of 1 M hydrochloric acid to a 0.1 M sodium acetate solution in 
water), with this mixture being degassed by sonication under 
vacuum for 30 min. Next, 3-glycidoxypropyltrimethoxysilane 
(1 ml) was added to this suspension. This mixture was shak-
en for 5 h at 90 °C. The epoxy silica formed by this reaction 
was washed several times with water and a pH 3.0 sulfuric acid 
solution. This support was then suspended in a pH 3.0 sulfuric 
acid solution (200 ml) and refl uxed for 90 min. This produced 
diol-bonded silica. This support was washed several times with 
water, methanol, and ether and dried overnight under vacuum at 
room temperature. The diol coverage on this support was mea-
sured in triplicate using an iodometric capillary electrophoresis 
assay [31], giving a value of 336 (±4) μmol diol groups/g silica.
This diol-bonded support is stable over several months 
when stored either under vacuum or in a neutral pH buffer. 
However, for the Schiff base method this material must next be 
converted into an aldehyde-activated form. This was accom-
plished by reacting the diol-bonded silica with periodic acid in 
the presence of a 90% (v/v) mixture of glacial acetic acid and 
water [30]. This aldehyde-activated support is known to have 
limited stability and was used for immobilization immediate-
ly after its preparation, as described in the next section. The 
epoxy silica, diol silica, aldehyde silica supports used for non-
specifi c binding studies were prepared in the same fashion as 
described in this section, with separate 2.1 mm i.d. × 3.5 cm or 
5.0 cm columns being packed with these materials.
2.5. Preparation of CDI control support
The CDI support for the non-specifi c binding studies was 
prepared as described in Ref. [32]. This was accomplished by 
combining 0.5 g of diol-bonded silica with 1 g of 1,1′-carbon-
yldiimidazole in 20 ml of dry acetonitrile and shaking at room 
temperature with a wrist action shaker for roughly 2 h. The 
resulting CDI-activated silica was then washed with approxi-
mately 200 ml of dry acetonitrile. This material was convert-
ed to an inactivated form (i.e., the form that would be pro-
duced after immobilization of a protein like HSA) by placing 
it into 0.5 M, pH 8 Tris buffer and reacting for 2 h at room 
temperature. This silica was then washed with 150 ml of pH 
7.4, 0.067 M potassium phosphate buffer and packed into a 
2.1 mm i.d. × 3.5 cm stainless steel column.
2.6. HSA immobilization
The immobilization of HSA to the NHS-activated silica 
was achieved by using a 20 mg/ml solution of HSA in pH 7.4, 
0.067 M potassium phosphate buffer. (Note: This buffer was 
prepared by placing 1.865 g potassium dihydrogen phosphate 
and 9.432 g dipotassium hydrogen phosphate in 900 ml water, 
adjusting the pH to 7.4 with a small volume of concentrated 
hydrochloric acid or sodium hydroxide, and diluting the buf-
fer to a total volume of 1.00 l with water.) A 3 ml aliquot of 
this solution was mixed with 0.2 g NHS-activated silica and 
reacted at room temperature for 2 h. After this reaction, the 
resulting HSA silica was washed several times with pH 7.4, 
0.067 M potassium phosphate buffer and stored in this buffer 
at 4 °C prior to use. A control support (i.e., the NHS control) 
was similarly prepared by placing 0.2 g NHS-activated sili-
ca into 3 ml of pH 7.4, 0.067 M potassium phosphate buffer 
for 2 h in the absence of any protein. This control silica was 
washed several times with the pH 7.4 buffer and stored under 
the same conditions as the immobilized HSA silica.
HSA was immobilized to aldehyde-activated silica in the 
Schiff base method by combining 150 mg HSA with 70 mg 
sodium cyanoborohydride and 5 g of the aldehyde-activated 
support in the presence of 10 ml of pH 6.0, 0.1 M potassium 
phosphate coupling buffer. (Note: This buffer was prepared by 
placing 11.86 g potassium dihydrogen phosphate and 2.24 g 
dipotassium hydrogen phosphate in 900 ml water, adjusting 
the pH to 6.0 with a small volume of concentrated hydrochlo-
ric acid or sodium hydroxide, and diluting the buffer to a total 
volume of 1 l with water.) This mixture was allowed to react 
for 5 days at 4 °C. After immobilization, the resulting HSA 
silica was washed several times with pH 7.4, 0.1 M potassium 
phosphate buffer and treated with three 10 mg portions of so-
dium borohydride to reduce any remaining aldehydes on the 
support to alcohol groups. The HSA silica was then washed 
several times with pH 7.4, 0.067 M potassium phosphate buf-
fer and stored in this buffer at 4 °C prior to use. A control 
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support was similarly prepared in the absence of protein and 
stored in the same manner as the immobilized HSA support.
The HSA coverage of each support was determined using a 
BCA protein assay. To perform this assay, a small portion (10–
20 mg) of each support was washed several times with deion-
ized water and dried under vacuum at room temperature. The 
amount of protein on this material was determined using HSA 
as the standard and the control support as the blank. With this 
procedure, the fi nal HSA content of the NHS support was found 
through triplicate measurements to be 125 (±18) nmol HSA/
g silica. The amount of HSA on the support prepared by the 
Schiff base method was 410 (±7) nmol HSA/g silica.
2.7. Chromatographic procedures
The immobilized HSA supports were packed into 2.1 mm 
i.d. × 5.0 cm stainless steel columns. The packing solution 
for these and all other supports used in this study was pH 7.4, 
0.067 M potassium phosphate buffer. Each column was placed 
in a water jacket for temperature control. All mobile phas-
es were degassed at least 15 min prior to use. The following 
wavelengths were used for detection: carbamazepine, 280 nm 
or 214 nm (the latter being used in the fi nal set of non-specif-
ic binding studies); digitoxin and phenytoin, 205 nm; lidocaine, 
propranolol, pindolol, verapamil and ibuprofen, 225 nm; tryp-
tophan, 280 nm; and warfarin, 309 nm. Column pressures less 
than 80 psi (0.55 MPa) were typically observed during the chro-
matographic studies, with no effects of pressure on the retention 
of carbamazepine being observed under these conditions.
Carbamazepine samples were prepared by dissolving this 
drug in pH 7.4, 0.067 M potassium phosphate buffer at con-
centrations of 0–50 μM. These solutions were stored at 4 °C 
until use, with carbamazepine being stable for several months 
under such conditions [27]. All other sample solutions were 
also prepared in pH 7.4, 0.067 M potassium phosphate buf-
fer. The tryptophan samples were used within 12 h of prepara-
tion. All other solutions were prepared and used over periods 
of less than 1 week.
Frontal analysis was performed by applying solutions of 
0–50 μM carbamazepine to the HSA or control columns at 
0.1 ml/min. This fl ow rate was well within the range needed 
to establish a local equilibrium in the HSA column, as deter-
mined in earlier studies [18, 20]. The retained carbamazepine 
was eluted by washing the column with pH 7.4, 0.067 M po-
tassium phosphate buffer. The amount of carbamazepine re-
quired to saturate the HSA or control columns was determined 
by integration to fi nd the mean position of the resulting break-
through curves [33]. The results obtained for the control col-
umns were subtracted from those obtained for HSA columns 
to correct for the void time and to adjust for any non-specifi c 
interactions between carbamazepine and the support’s surface. 
The void times for the HSA columns and control columns were 
estimated by injecting sodium nitrate as a non-retained solute.
The stability of each HSA column was checked periodi-
cally over the course of this study (i.e., 6 months and approxi-
mately 500 column volumes). This was accomplished by mak-
ing periodic injections of carbamazepine under a set of stan-
dard conditions (i.e., pH 7.4, 0.067 M phosphate buffer ap-
plied at 25 °C and 0.1 ml/min). Less than a 3% change in re-
tention was observed for both the Schiff base and NHS col-
umns during the work described in this report. The non-spe-
cifi c binding studies based on zonal elution experiments were 
performed using 20 μl sample injections of the following so-
lutions in pH 7.4, 0.067 M phosphate buffer: 10 μM digitox-
in, propranolol, tryptophan or pindolol; 20 μM lidocaine, pin-
dolol, warfarin, ibuprofen, verapamil or phenytoin; and 5 μM 
carbamazepine. All of these non-specifi c binding studies were 
performed in at least triplicate at 37 °C and 1.0 ml/min. The 
void time in the zonal elution studies was determined using 
DMSO as a non-retained solute.
3. Results and discussion
3.1. General retention properties of the HSA columns
The fi rst item studied was the relative degree of retention 
of carbamazepine on HSA columns prepared by the NHS and 
Schiff base methods. Figure 2 gives typical chromatograms 
obtained for carbamazepine on these columns as well as on 
the corresponding control columns. It can be seen from these 
results that both types of HSA columns gave good retention 
for this drug, with total retention factors of 3.36 and 5.40 be-
ing measured on columns prepared by the NHS and Schiff 
base methods, respectively. 
However, one signifi cant difference in these immobili-
zation methods was the amount of non-specifi c adsorption 
that occurred between carbamazepine and the control col-
Figure 2. Typical chromatograms for carbamazepine on 2.1 mm i.d. × 5.0 cm 
HSA columns and control columns prepared by the (a) Schiff base method or 
(b) NHS method. 
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umns. This is demonstrated in Table 1. For instance, although 
the overall retention for carbamazepine on the Schiff base 
HSA column was 1.6-fold higher than on the NHS-prepared 
column, more than half of the retention seen for the Schiff 
base column (55.7%) was also noted on its control support 
(k = 3.01). On the other hand, the control column for the NHS 
method gave retention for carbamazepine that was only 11.9% 
of that seen on the NHS immobilized HSA column (k = 0.40). 
Thus, it was found that substantially less non-specifi c binding 
occurred for carbamazepine when using the NHS method. 
In the Schiff base method, 3-glycidoxypropyltrime-
thoxysilane was reacted with the silica to place epoxy groups, 
and later aldehyde groups, on the support’s surface. This re-
sulting in a material with a propyl group on the support as a 
spacer between the surface and amine-reactive sites; alcohol 
groups were also present at the end of this support after it had 
been used in immobilization or inactivated. However, no such 
spacer or groups were present in support prepared by the NHS 
method. In the NHS method, DSC was reacted directly with 
silanols to form an active NHS ester. After these NHS groups 
had been used in immobilization, any remaining active sites 
were removed by hydrolysis [28]. This explains why the NHS 
control column gave similar results to a bare silica column. A 
further consideration of the sources of this non-specifi c bind-
ing is given later in Section 3.5.
3.2. Binding capacity measurements
The binding of carbamazepine to the HSA columns was ex-
amined in more detail by using frontal analysis [34–36]. This 
method involved applying a known concentration of the test 
solute continuously to a column containing the immobilized li-
gand of interest. As the amount of solute that was bound by the 
column increased, this formed a breakthrough curve, where the 
mean point of this curve was related to the concentration of ap-
plied solute and the amount of immobilized ligand.
If an applied solute (S) binds only to a single type of site 
on the ligand (L) and this binding has relatively fast associ-
ation/dissociation kinetics, the following relationship can be 
used to relate the true number of active ligand binding sites 
on the column (mL) to the apparent moles of solute (mLapp) re-
quired to reach the mean point of the breakthrough curve [18, 
36]. This is shown in Equation (1),
   (1)
where Ka is the concentration-dependent association equilib-
rium constant for the binding of S to L, and [S] is the concen-
tration of solute applied to the column. Equation (1) predicts 
that a plot of 1/mLapp versus 1/[S] will give a straight line for 
a system with 1:1 binding. Furthermore, this line will have a 
slope equal to 1/(KamL) and an intercept of 1/mL. This makes 
it possible to obtain the association equilibrium constant Ka by 
taking the ratio of the intercept to the slope. In addition, the 
true number of binding sites (mL) in the column can be deter-
mined from the inverse of the intercept [18].
In correcting for non-specifi c adsorption, it has been shown 
that subtracting the breakthrough times for a control column 
from that obtained for an immobilized HSA column gives a 
good estimate for the specifi c interactions between an applied 
drug and HSA [27]. In this particular study, it was found with 
the Schiff base columns that this correction gave association 
equilibrium constants at all tested temperatures that were with-
in 5–15% of those determined using a more complex multi-site 
model. An even better correlation would be expected for the 
NHS results due to the lower amount of non-specifi c binding 
that was observed for carbamazepine with the NHS support.
The frontal analysis results obtained in this study are sum-
marized in Figure 3. For both the NHS and Schiff base meth-
ods, plots of 1/mLapp versus 1/[carbamazepine] gave linear 
relationships over the entire concentration range studied at 
37 °C. The correlation coeffi cients for these plots were 0.9997 
(Schiff base data) and 0.9999 (NHS data) for six data points. 
According to Equation (1), this linear behavior indicated that 
carbamazepine was binding to a single type of site on the im-
mobilized HSA. This same conclusion has been reached in 
previous work with carbamazepine and HSA in solution phase 
studies [27]. 
From the intercepts of the plots shown in Figure 3, it was 
possible to estimate the moles of active binding sites for car-
bamazepine on each HSA column. Table 2 shows the values 
Figure 3. Double-reciprocal plots obtained for frontal analysis studies with 
carbamazepine at pH 7.4 and 37 °C using HSA immobilized by the NHS 
method (■) or Schiff base method (□). 
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obtained at several temperatures. Both columns gave a simi-
lar trend in the binding capacity as the temperature increased. 
The HSA column made by the Schiff base method consistent-
ly gave the highest binding capacity (14–43% larger than the 
NHS prepared column), but this column also contained more 
immobilized protein. 
Using the known protein content of each support and the 
measured binding capacities, it was possible to determine 
the specifi c activity for each type of immobilized HSA col-
umn. These results are given in Table 2. It was found that the 
NHS and Schiff base methods gave comparable activities for 
the immobilized HSA when measured at 37 °C, with values 
of 72–75%. However, this activity changed with temperature, 
with HSA immobilized by the NHS method showing a larger 
variation than that prepared by the Schiff base technique. The 
reason for this is not yet clear, but it may indicate that differ-
ent degrees of multi-site attachment occur between HSA and 
the support in these two methods. This, in turn, would affect 
the ability of the HSA to alter its conformation with tempera-
ture. If this is the case, HSA immobilized by the Schiff base 
method appears to be less fl exible in its structure since its ac-
tivity is more stable with regards to changes in temperature.
3.3. Association equilibrium constant measurements
In addition to the binding capacity, the association equilib-
rium constant for carbamazepine with HSA was obtained from 
the plots in Figure 3. Table 3 shows the values obtained over 
4–45 °C for the NHS and Schiff base columns. Both columns 
gave similar trends in the association equilibrium constants as 
the temperature was varied, with a decrease of fi ve- to six-
fold in Ka as the temperature was raised from 4 to 45 °C. This 
same trend has been seen for other compounds, including l-
tryptophan, R-warfarin, S-warfarin and l-thyroxine [19, 36]. 
The association equilibrium constant for carbamaze-
pine with immobilized HSA prepared by either method was 
(5.3–5.5) × 103 M−1 at 37 °C. This is similar to earlier re-
sults obtained in solution phase studies using microdialy-
sis or HPLC, in which association equilibrium constants of 
(0.7–1.0) × 104 M−1 have been reported [37]. The similarity of 
these values indicates that the immobilized HSA was a good 
model for the binding of HSA in solution. The fact that the 
Schiff base and NHS methods gave essentially identical asso-
ciation equilibrium constants at all of the temperatures stud-
ied again indicates that it was the relative amount of active 
protein, rather than the equilibrium constants for HSA, which 
gave rise to the differences in specifi c activity observed in Ta-
ble 2 for these two methods.
3.4. Thermodynamic studies
Thermodynamic parameters for the HSA columns were 
determined by using the concentration-dependent association 
equilibrium constants in Table 3 to prepare van’t Hoff plots. 
This was accomplished by using Equation (2),
   (2)
where Ka is the association equilibrium constant for the bind-
ing of solute to ligand, T the absolute temperature, and R is the 
gas law constant [36]. Other terms in Equation (2) include the 
changes in entropy (ΔS) and enthalpy (ΔH) for the solute-pro-
tein interaction. Equation (2) indicates that a system with 1:1 in-
teractions will give a plot for ln Ka versus 1/T that produces a 
straight line with a slope equal to −ΔH/R and an intercept of ΔS/
R. The changes of enthalpy and entropy can be directly calculat-
ed from the slope and intercept of this plot, respectively. In addi-
tion, the total change in Gibbs free energy (ΔG) can be obtained 
by using Equation (3) along with measured values of T and Ka.
ΔG=−RT ln(Ka)    (3)
The resulting graphs of ln Ka versus 1/T obtained for the 
NHS and Schiff base immobilized HSA columns are shown in 
Figure 4. Both plots gave linear behavior with correlation co-
effi cients of 0.977 and 0.971 (n = 5) for the NHS and Schiff 
base data, respectively. This linearity further confi rmed there 
was a single type of binding site for carbamazepine on the 
HSA immobilized by either the NHS or Schiff base method. 
The two plots shown in Figure 4 were statistically identi-
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cal over the range of temperatures given. From the slopes and 
intercepts of these plots, it was possible to estimate the chang-
es in the total Gibbs free energy, enthalpy, and entropy for the 
binding of carbamazepine with the immobilized HSA col-
umns. The results indicated that the binding of carbamazepine 
to HSA gave a large change in enthalpy of −27 to −35 kJ/mol, 
or −6.5 to −8.4 kcal/mol. This was accompanied by a decrease 
in entropy for the system, as represented by changes in entro-
py of −15.0 to −42.7 J/(mol K), or −3.6 to −10.2 cal/(mol K). 
The total changes in Gibbs free energy measured for the bind-
ing of carbamazepine on HSA with these columns was −21.7 
to −22.4 kJ/mol at 37 °C (i.e., −5.2 to −5.35 kcal/mol).
These results indicate that a change in enthalpy is the 
main driving force for carbamazepine–HSA binding, with this 
working in opposition to a decrease in entropy to produce a 
stable complex. The decrease in entropy seen upon the bind-
ing of carbamazepine to HSA is somewhat unusual in that 
most drugs show an increase in entropy when binding to this 
protein [38]. However, a decrease in entropy has been noted 
in some previous cases, such as binding of benzodiazepines or 
heptacarboxyl porphyrin to HSA [39–41].
3.5. Sources of non-specifi c binding by carbamazepine and 
other solutes
The last section of this study compared the possible sourc-
es of non-specifi c binding for carbamazapine in the HSA col-
umns that were prepared by the Schiff base and NHS-activa-
tion methods. This was done by taking samples of these sup-
ports at each stage of their synthesis, placing these materials 
into columns and comparing their retention for carbamaze-
pine under the same mobile phase conditions as used in the 
work with immobilized HSA. The results are summarized in 
Table 4. 
First, a comparison was made between the retention fac-
tors measured for carbamazepine on the Schiff base con-
trol column versus bare silica and supports collected at vari-
ous stages of the Schiff base immobilization process. For both 
carbamazepine and the other tested solutes, a close correlation 
was noted between the non-specifi c binding seen on the Schiff 
base columns and diol silica. This was not surprising since 
the surfaces of these two supports differ by only one alcohol 
group at the end of their organosilane chains (i.e., two in the 
diol silica and one in the Schiff base control). Although the 
aldehyde silica gave higher non-specifi c binding for carbam-
azepine than the Schiff base control, aldehyde groups should 
not have been present in the fi nal Schiff base support due to 
the use of sodium borohydride as a reducing agent to remove 
these groups at the end of this immobilization process. Some 
non-specifi c binding due to the propyl backbone of organosi-
lane chains may also have been present (as suggested by the 
epoxy silica results), but the increase in retention between the 
epoxy and diol silica results indicates that the terminal alcohol 
groups on these chains were the main source of non-specifi c 
binding for carbamazepine in these particular materials.
A similar comparison was made between the retention fac-
tors on bare silica and the NHS control support. The results 
were quite similar for carbamazepine, indicating that the sili-
Figure 4. A van’t Hoff plot for the interactions of carbamazepine with HSA 
immobilized by the NHS method (■) or Schiff base method (□). The best-fi t 
slope and intercept for the NHS column were 4.21 (±0.07) × 103 and −5.14 
(±0.39), respectively. The best-fi t slope and intercept for Schiff base column 
were 3.24 (±0.02) × 103 and −1.76 (±0.01). The correlation coeffi cient was 
0.977 (n = 5) for the NHS column and 0.971 (n = 5) for the Schiff base col-
umn. 
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ca itself was the source of the relatively small amount of non-
specifi c binding seen when using carbamazepine with HSA 
that had been immobilized by this method. This was not sur-
prising since the conditions used in this study for the NHS 
method gave rise to only a small amount of activation for this 
support, leaving the rest of the surface available for possible 
interactions with the injected solutes.
The non-specifi c binding by other solutes were also com-
pared in the Schiff base and NHS supports. These solutes in-
cluded several compounds that are commonly used as site-se-
lective probes for HSA (i.e., tryptophan, warfarin, and digi-
toxin) and a variety of drugs that are known to have signifi -
cant binding to this protein (e.g., lidocaine, propranolol, pin-
dolol, ibuprofen, phenytoin, and verapamil) [3–5, 18]. As was 
seen for carbamazepine, some of these solutes gave lower 
non-specifi c binding on the NHS support than on the Schiff 
base support; these solutes included tryptophan, warfarin, pro-
pranolol, ibuprofen, and phenytoin. However, there were also 
several of these compounds that gave lower non-specifi c bind-
ing when using the Schiff base method (e.g., digitoxin, pindo-
lol, and verapamil).
One additional immobilization method that was con-
sidered in this comparison of non-specifi c binding was the 
CDI method. This was examined since it has also been used 
in many studies for the immobilization of HSA to silica, al-
though it has been observed to give lower activity for this pro-
tein than the Schiff base method [18, 42]. For carbamazepine, 
the CDI method gave greater non-specifi c binding than either 
the Schiff base or NHS methods. This was also the case for 
tryptophan, warfarin, propranolol, pindolol, ibuprofen, and 
phenytoin. The CDI method gave lower non-specifi c binding 
than these other immobilization techniques for only two of the 
tested compounds (lidocaine and verapamil) and gave non-
specifi c binding between that of these other methods for one 
solute (digitoxin).
4. Conclusions
This study examined the binding between HSA and carba-
mazepine by using HSA columns prepared by two immobili-
zation techniques: the Schiff base and the NHS method. The 
NHS column was prepared by immobilizing HSA to silica that 
had been directly modifi ed with DSC. It was found that the 
Schiff base and NHS columns gave comparable equilibrium 
constants, activities, and thermodynamic parameters for car-
bamazepine–HSA binding, making them both useful in creat-
ing columns for studies of this interaction. However, the NHS 
method gave a support with much less non-specifi c binding 
for carbamazepine than supports prepared by the Schiff base 
method.
The results obtained in this study indicate that the NHS 
method is a useful alternative to the Schiff base method for 
work with carbamazepine. However, as is demonstrated in Ta-
ble 4, the selection of an immobilization method for HSA still 
should be considered on a case-by-case basis in drug–protein 
interaction studies by HPAC. This is agreement with recent 
work with related NHS-activated supports (created by treat-
ing aminopropyl silica with disuccinimidyl suberate), which 
gave comparable non-specifi c binding to Schiff base-activated 
supports for d- and l-tryptophan but higher non-specifi c bind-
ing for R- and S-warfarin [43]. Thus, it is recommended that 
several immobilization techniques (e.g., the Schiff base, NHS, 
and CDI methods), be considered in initial experiments with 
other solutes in drug binding studies based on HPAC and HSA 
columns. 
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